Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eikon Therapeutics
Biotech
Eikon remains in megaround mode with $350M series D
Eikon is no stranger to megarounds, and the cancer-focused biotech has continued this trend with $350 million to fuel its clinical trials.
James Waldron
Feb 26, 2025 9:40am
Pfizer replaces retiring CSO with cancer chief—Chutes & Ladders
Nov 22, 2024 8:30am
Eikon, Dewpoint investors raise new $630 million fund
Jan 29, 2024 9:39am
Eikon cuts staff to 'become more efficient,' CEO says
Oct 7, 2023 6:36pm
Eikon builds out clinical development team—Chutes & Ladders
Jun 2, 2023 9:30am
Eikon snaps up clinical pipeline thanks to 'buyer's market'
Jun 1, 2023 8:00am
